RU2019135533A - Анализ измерения эффективности рецепторно-лигандных взаимодействий в лекарственных нанолекарственных средствах - Google Patents
Анализ измерения эффективности рецепторно-лигандных взаимодействий в лекарственных нанолекарственных средствах Download PDFInfo
- Publication number
- RU2019135533A RU2019135533A RU2019135533A RU2019135533A RU2019135533A RU 2019135533 A RU2019135533 A RU 2019135533A RU 2019135533 A RU2019135533 A RU 2019135533A RU 2019135533 A RU2019135533 A RU 2019135533A RU 2019135533 A RU2019135533 A RU 2019135533A
- Authority
- RU
- Russia
- Prior art keywords
- antigen
- cell
- paragraphs
- disease
- tcr
- Prior art date
Links
- 229940079593 drug Drugs 0.000 title claims 3
- 239000003814 drug Substances 0.000 title claims 3
- 230000003993 interaction Effects 0.000 title 1
- 239000003446 ligand Substances 0.000 title 1
- 239000000427 antigen Substances 0.000 claims 106
- 108091007433 antigens Proteins 0.000 claims 106
- 102000036639 antigens Human genes 0.000 claims 106
- 108091008874 T cell receptors Proteins 0.000 claims 43
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 43
- 210000004027 cell Anatomy 0.000 claims 41
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 16
- 238000000034 method Methods 0.000 claims 16
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 14
- 201000010099 disease Diseases 0.000 claims 13
- 229920001184 polypeptide Polymers 0.000 claims 12
- 108090000765 processed proteins & peptides Proteins 0.000 claims 12
- 102000004196 processed proteins & peptides Human genes 0.000 claims 12
- 239000002105 nanoparticle Substances 0.000 claims 11
- 230000001419 dependent effect Effects 0.000 claims 10
- 230000037361 pathway Effects 0.000 claims 10
- 102000040430 polynucleotide Human genes 0.000 claims 8
- 108091033319 polynucleotide Proteins 0.000 claims 8
- 239000002157 polynucleotide Substances 0.000 claims 8
- 108700018351 Major Histocompatibility Complex Proteins 0.000 claims 7
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 claims 7
- 208000023275 Autoimmune disease Diseases 0.000 claims 6
- 206010008609 Cholangitis sclerosing Diseases 0.000 claims 6
- 241000721454 Pemphigus Species 0.000 claims 6
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims 6
- 208000006673 asthma Diseases 0.000 claims 6
- 230000001363 autoimmune Effects 0.000 claims 6
- 208000027866 inflammatory disease Diseases 0.000 claims 6
- 150000007523 nucleic acids Chemical group 0.000 claims 6
- 230000004044 response Effects 0.000 claims 6
- 208000010157 sclerosing cholangitis Diseases 0.000 claims 6
- 108700026220 vif Genes Proteins 0.000 claims 6
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 claims 4
- 108091023040 Transcription factor Proteins 0.000 claims 4
- 102000040945 Transcription factor Human genes 0.000 claims 4
- 230000000694 effects Effects 0.000 claims 4
- 238000000338 in vitro Methods 0.000 claims 4
- 230000009885 systemic effect Effects 0.000 claims 4
- XGWFJBFNAQHLEF-UHFFFAOYSA-N 9-anthroic acid Chemical compound C1=CC=C2C(C(=O)O)=C(C=CC=C3)C3=CC2=C1 XGWFJBFNAQHLEF-UHFFFAOYSA-N 0.000 claims 3
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 claims 3
- 208000030767 Autoimmune encephalitis Diseases 0.000 claims 3
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 3
- 208000015943 Coeliac disease Diseases 0.000 claims 3
- 206010016654 Fibrosis Diseases 0.000 claims 3
- 208000024869 Goodpasture syndrome Diseases 0.000 claims 3
- 208000003807 Graves Disease Diseases 0.000 claims 3
- 208000015023 Graves' disease Diseases 0.000 claims 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 3
- 208000011200 Kawasaki disease Diseases 0.000 claims 3
- 108060001084 Luciferase Proteins 0.000 claims 3
- 239000005089 Luciferase Substances 0.000 claims 3
- 201000004681 Psoriasis Diseases 0.000 claims 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 3
- 206010046851 Uveitis Diseases 0.000 claims 3
- 206010047115 Vasculitis Diseases 0.000 claims 3
- 201000009961 allergic asthma Diseases 0.000 claims 3
- 206010003246 arthritis Diseases 0.000 claims 3
- 201000004984 autoimmune cardiomyopathy Diseases 0.000 claims 3
- 201000004982 autoimmune uveitis Diseases 0.000 claims 3
- 230000007882 cirrhosis Effects 0.000 claims 3
- 208000019425 cirrhosis of liver Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 claims 3
- 201000006417 multiple sclerosis Diseases 0.000 claims 3
- 206010028417 myasthenia gravis Diseases 0.000 claims 3
- 208000033808 peripheral neuropathy Diseases 0.000 claims 3
- 201000000742 primary sclerosing cholangitis Diseases 0.000 claims 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 3
- 238000001228 spectrum Methods 0.000 claims 3
- 208000011580 syndromic disease Diseases 0.000 claims 3
- 102000015936 AP-1 transcription factor Human genes 0.000 claims 2
- 108050004195 AP-1 transcription factor Proteins 0.000 claims 2
- 102000004190 Enzymes Human genes 0.000 claims 2
- 108090000790 Enzymes Proteins 0.000 claims 2
- 108010002350 Interleukin-2 Proteins 0.000 claims 2
- 101000574441 Mus musculus Alkaline phosphatase, germ cell type Proteins 0.000 claims 2
- 108010057466 NF-kappa B Proteins 0.000 claims 2
- 102000003945 NF-kappa B Human genes 0.000 claims 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims 2
- 239000013642 negative control Substances 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 238000011002 quantification Methods 0.000 claims 2
- 238000013518 transcription Methods 0.000 claims 2
- 230000035897 transcription Effects 0.000 claims 2
- 102000003992 Peroxidases Human genes 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 230000000890 antigenic effect Effects 0.000 claims 1
- 238000003556 assay Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000002184 metal Substances 0.000 claims 1
- 108040007629 peroxidase activity proteins Proteins 0.000 claims 1
- 238000003908 quality control method Methods 0.000 claims 1
- 210000003370 receptor cell Anatomy 0.000 claims 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56977—HLA or MHC typing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/605—MHC molecules or ligands thereof
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/902—Oxidoreductases (1.)
- G01N2333/90241—Oxidoreductases (1.) acting on single donors with incorporation of molecular oxygen, i.e. oxygenases (1.13)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Wood Science & Technology (AREA)
- Virology (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Rheumatology (AREA)
- Mycology (AREA)
- Nanotechnology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762483298P | 2017-04-07 | 2017-04-07 | |
| US62/483,298 | 2017-04-07 | ||
| PCT/IB2018/000510 WO2018185564A2 (en) | 2017-04-07 | 2018-04-05 | Assay to measure the potency of receptor-ligand interactions in nanomedicines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2019135533A true RU2019135533A (ru) | 2021-05-07 |
Family
ID=63713282
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2019135533A RU2019135533A (ru) | 2017-04-07 | 2018-04-05 | Анализ измерения эффективности рецепторно-лигандных взаимодействий в лекарственных нанолекарственных средствах |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20200057048A1 (https=) |
| EP (1) | EP3607058A4 (https=) |
| JP (2) | JP2020516594A (https=) |
| KR (1) | KR20200004807A (https=) |
| CN (1) | CN110945120B (https=) |
| AU (1) | AU2018248961B2 (https=) |
| BR (1) | BR112019021022A2 (https=) |
| CO (1) | CO2019011018A2 (https=) |
| IL (1) | IL269846A (https=) |
| MX (1) | MX2019012058A (https=) |
| RU (1) | RU2019135533A (https=) |
| SG (1) | SG11201909290TA (https=) |
| WO (1) | WO2018185564A2 (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2836343C1 (ru) * | 2024-01-25 | 2025-03-13 | Федеральное Государственное Бюджетное Учреждение Науки Институт Молекулярной Биологии Им. В.А. Энгельгардта Российской Академии Наук (Имб Ран) | Безопасная клеточная репортерная система для поиска нуклеозидных и ненуклеозидных ингибиторов рнк-зависимой рнк-полимеразы sars-cov-2 |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9511151B2 (en) | 2010-11-12 | 2016-12-06 | Uti Limited Partnership | Compositions and methods for the prevention and treatment of cancer |
| US10988516B2 (en) | 2012-03-26 | 2021-04-27 | Uti Limited Partnership | Methods and compositions for treating inflammation |
| US9603948B2 (en) | 2012-10-11 | 2017-03-28 | Uti Limited Partnership | Methods and compositions for treating multiple sclerosis and related disorders |
| SG10201803780UA (en) | 2013-11-04 | 2018-06-28 | Uti Lp | Methods and compositions for sustained immunotherapy |
| ES3055030T3 (en) | 2015-05-06 | 2026-02-09 | Uti Lp | Nanoparticle compositions for sustained therapy |
| EP3716949A4 (en) | 2017-11-29 | 2022-05-18 | UTI Limited Partnership | Methods of treating autoimmune disease |
| CN112585162B (zh) * | 2018-08-06 | 2025-01-28 | 基因医疗免疫疗法有限责任公司 | Ha-1特异性t细胞受体及其用途 |
| GB201906127D0 (en) * | 2019-05-01 | 2019-06-12 | Immutep S A | Assays |
| EP3958892A4 (en) * | 2019-05-23 | 2023-06-14 | UTI Limited Partnership | METHOD OF TREATMENT OF LIVER DISEASE |
| KR20220150276A (ko) * | 2020-01-11 | 2022-11-10 | 시벡 바이오테크놀로지스, 엘엘씨 | 진핵생물로의 진핵생물-번역가능한 mRNA의 생산 및 전달을 위한 미생물 시스템 |
| CN115917654A (zh) * | 2020-04-21 | 2023-04-04 | 瑞泽恩制药公司 | 用于分析受体相互作用的方法和系统 |
| WO2021148683A2 (en) * | 2020-05-06 | 2021-07-29 | Imcyse Sa | Peptides and methods for the treatment of multiple sclerosis |
| TW202208395A (zh) | 2020-05-12 | 2022-03-01 | 美商信號生物製藥公司 | 多聚體ｔ細胞調節多肽及其使用方法 |
| EP4211149A4 (en) * | 2020-09-09 | 2024-10-09 | Cue Biopharma, Inc. | MULTIMERIC POLYPEPTIDES MODULATING MHC CLASS II T CELLS FOR THE TREATMENT OF TYPE 1 DIABETES MELLITUS (T1D) AND METHODS OF USE THEREOF |
| CA3232037A1 (en) * | 2021-09-21 | 2023-03-30 | Monash University | Methods of treatment |
| CN113960003B (zh) * | 2021-10-20 | 2023-10-24 | 吉林大学 | 基于dna银纳米簇和金纳米棒检测四环素的适配体传感器 |
| US11873507B2 (en) * | 2021-11-29 | 2024-01-16 | Replicate Bioscience, Inc. | Compositions and methods for expression of IL-12 and IL-1RA |
| EP4249062A1 (en) * | 2022-03-24 | 2023-09-27 | Julius-Maximilians-Universität Würzburg | Mhc ib-mediated aquaporin 4 (aqp4)-specific immunosuppression as a novel treatment for nmo |
| CN115125205A (zh) * | 2022-06-14 | 2022-09-30 | 中国医学科学院生物医学工程研究所 | 一种修饰EpCAM抗体和/或CSV抗体的白细胞磁球及其制备方法 |
| WO2024248042A1 (ja) * | 2023-05-29 | 2024-12-05 | 国立大学法人 東京大学 | ＭｕＳＫを標的とする新規化合物及びその用途 |
| AU2024346292A1 (en) * | 2023-09-22 | 2026-04-02 | Julius-Maximilians-Universität Würzburg, In Vertretung Des Freistaates Bayern | Mhc ib-mediated aquaporin 4 (aqp4)-specific immunosuppression as a novel treatment for nmo |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US707993A (en) | 1901-05-16 | 1902-08-26 | Clinton J Warren | Machine for corking bottles. |
| US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
| US6103379A (en) | 1994-10-06 | 2000-08-15 | Bar-Ilan University | Process for the preparation of microspheres and microspheres made thereby |
| WO1996018105A1 (en) | 1994-12-06 | 1996-06-13 | The President And Fellows Of Harvard College | Single chain t-cell receptor |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US6924123B2 (en) | 1996-10-29 | 2005-08-02 | Oxford Biomedica (Uk) Limited | Lentiviral LTR-deleted vector |
| AU3896699A (en) | 1998-05-07 | 1999-11-23 | Regents Of The University Of California, The | Use of neglected target tissue antigens in modulation of immune responses |
| US6150022A (en) | 1998-12-07 | 2000-11-21 | Flex Products, Inc. | Bright metal flake based pigments |
| US7419829B2 (en) | 2000-10-06 | 2008-09-02 | Oxford Biomedica (Uk) Limited | Vector system |
| KR100379250B1 (ko) | 2000-12-04 | 2003-04-08 | 한국과학기술연구원 | 나노 단위 크기의 금속 입자가 함유된 고분자 복합 소재및 그 제조 방법 |
| DE60226852D1 (de) | 2001-03-13 | 2008-07-10 | Novartis Ag | Lentivirale verpackungskonstrukte |
| GB0417954D0 (en) * | 2004-08-12 | 2004-09-15 | Avidex Ltd | Cellulat TCR ligand assay method |
| AU2008222678B2 (en) * | 2007-03-07 | 2013-01-17 | The General Hospital Corporation | Compositions and methods for the prevention and treatment of autoimmune conditions |
| WO2009027978A1 (en) | 2007-08-30 | 2009-03-05 | Hadasit Medical Research Services & Development Ltd. | NUCLEIC ACID SEQUENCES COMPRISING NF-ϰB BINDING SITE WITHIN O(6)-METHYLGUANINE-DNA-METHYLTRANSFERASE (MGMT) PROMOTER REGION AND USES THEREOF FOR THE TREATMENT OF CANCER AND IMMUNE-RELATED DISORDERS |
| WO2010055510A2 (en) | 2008-11-12 | 2010-05-20 | Yeda Research And Development Co. Ltd. | Diagnosis of multiple sclerosis |
| CA2777053A1 (en) | 2009-10-06 | 2011-04-14 | The Board Of Trustees Of The University Of Illinois | Human single-chain t cell receptors |
| CA2813064C (en) | 2010-09-29 | 2021-06-01 | Uti Limited Partnership | Methods for treating autoimmune disease using biocompatible bioabsorbable nanospheres |
| US9511151B2 (en) | 2010-11-12 | 2016-12-06 | Uti Limited Partnership | Compositions and methods for the prevention and treatment of cancer |
| WO2013057586A1 (en) | 2011-10-19 | 2013-04-25 | Oslo Universitetssykehus Hf | Compositions and methods for producing soluble t - cell receptors |
| US8809057B2 (en) * | 2012-01-04 | 2014-08-19 | Raytheon Bbn Technologies Corp. | Methods of evaluating gene expression levels |
| US10988516B2 (en) | 2012-03-26 | 2021-04-27 | Uti Limited Partnership | Methods and compositions for treating inflammation |
| JP6014440B2 (ja) | 2012-09-26 | 2016-10-25 | 日立オートモティブシステムズ株式会社 | 移動物体認識装置 |
| SG10201803780UA (en) | 2013-11-04 | 2018-06-28 | Uti Lp | Methods and compositions for sustained immunotherapy |
| DK3220927T3 (en) * | 2014-11-20 | 2022-02-14 | Promega Corp | Systems and methods for assessing modulators of immune checkpoints |
| EP3233903B1 (en) * | 2014-12-19 | 2020-12-09 | ETH Zürich | Chimeric antigen receptors and methods of use |
| EP3067366A1 (en) * | 2015-03-13 | 2016-09-14 | Max-Delbrück-Centrum Für Molekulare Medizin | Combined T cell receptor gene therapy of cancer against MHC I and MHC II-restricted epitopes of the tumor antigen NY-ESO-1 |
| KR20260048600A (ko) * | 2015-03-27 | 2026-04-10 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 변형된 t 세포 및 이의 제조 및 사용 방법 |
| ES3055030T3 (en) * | 2015-05-06 | 2026-02-09 | Uti Lp | Nanoparticle compositions for sustained therapy |
| HK1253694A1 (zh) * | 2015-06-01 | 2019-06-28 | Medigene Immunotherapies Gmbh | T细胞受体文库 |
| JP2018531593A (ja) * | 2015-09-11 | 2018-11-01 | アジェナス インコーポレイテッド | 操作された宿主細胞及びそれらの使用方法 |
-
2018
- 2018-04-05 CN CN201880038292.4A patent/CN110945120B/zh active Active
- 2018-04-05 BR BR112019021022A patent/BR112019021022A2/pt not_active Application Discontinuation
- 2018-04-05 EP EP18781139.3A patent/EP3607058A4/en active Pending
- 2018-04-05 AU AU2018248961A patent/AU2018248961B2/en active Active
- 2018-04-05 MX MX2019012058A patent/MX2019012058A/es unknown
- 2018-04-05 SG SG11201909290T patent/SG11201909290TA/en unknown
- 2018-04-05 JP JP2019554417A patent/JP2020516594A/ja active Pending
- 2018-04-05 WO PCT/IB2018/000510 patent/WO2018185564A2/en not_active Ceased
- 2018-04-05 RU RU2019135533A patent/RU2019135533A/ru not_active Application Discontinuation
- 2018-04-05 KR KR1020197032951A patent/KR20200004807A/ko not_active Withdrawn
- 2018-04-05 US US16/603,180 patent/US20200057048A1/en not_active Abandoned
-
2019
- 2019-10-04 CO CONC2019/0011018A patent/CO2019011018A2/es unknown
- 2019-10-06 IL IL26984619A patent/IL269846A/en unknown
-
2023
- 2023-09-01 US US18/459,960 patent/US20240201171A1/en active Pending
-
2024
- 2024-02-21 JP JP2024024899A patent/JP2024073459A/ja active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2836343C1 (ru) * | 2024-01-25 | 2025-03-13 | Федеральное Государственное Бюджетное Учреждение Науки Институт Молекулярной Биологии Им. В.А. Энгельгардта Российской Академии Наук (Имб Ран) | Безопасная клеточная репортерная система для поиска нуклеозидных и ненуклеозидных ингибиторов рнк-зависимой рнк-полимеразы sars-cov-2 |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2020516594A (ja) | 2020-06-11 |
| US20240201171A1 (en) | 2024-06-20 |
| BR112019021022A2 (pt) | 2020-06-09 |
| SG11201909290TA (en) | 2019-11-28 |
| CN110945120A (zh) | 2020-03-31 |
| AU2018248961A1 (en) | 2019-10-31 |
| MX2019012058A (es) | 2019-11-11 |
| WO2018185564A2 (en) | 2018-10-11 |
| AU2018248961B2 (en) | 2024-06-20 |
| WO2018185564A3 (en) | 2019-01-03 |
| EP3607058A4 (en) | 2020-12-16 |
| CA3059016A1 (en) | 2018-10-11 |
| KR20200004807A (ko) | 2020-01-14 |
| JP2024073459A (ja) | 2024-05-29 |
| IL269846A (en) | 2019-11-28 |
| US20200057048A1 (en) | 2020-02-20 |
| CO2019011018A2 (es) | 2019-10-21 |
| CN110945120B (zh) | 2025-04-18 |
| EP3607058A2 (en) | 2020-02-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2019135533A (ru) | Анализ измерения эффективности рецепторно-лигандных взаимодействий в лекарственных нанолекарственных средствах | |
| Walters et al. | Characterization of CCX282-B, an orally bioavailable antagonist of the CCR9 chemokine receptor, for treatment of inflammatory bowel disease | |
| JP2020516594A5 (https=) | ||
| Müller et al. | The CHR site: definition and genome-wide identification of a cell cycle transcriptional element | |
| Kaiser et al. | The dystonia gene DYT1 is repressed by the transcription factor THAP1 (DYT6) | |
| Goodier et al. | Discrete subcellular partitioning of human retrotransposon RNAs despite a common mechanism of genome insertion | |
| Blumberg et al. | Interleukin 20: discovery, receptor identification, and role in epidermal function | |
| Liao et al. | Priming for T helper type 2 differentiation by interleukin 2–mediated induction of interleukin 4 receptor α-chain expression | |
| Welch et al. | PTC124 targets genetic disorders caused by nonsense mutations | |
| Mekhail et al. | Role for perinuclear chromosome tethering in maintenance of genome stability | |
| Wolf et al. | Asc1, homolog of human RACK1, prevents frameshifting in yeast by ribosomes stalled at CGA codon repeats | |
| Ahlfors et al. | SATB1 dictates expression of multiple genes including IL-5 involved in human T helper cell differentiation | |
| Bartlett et al. | Defining critical roles for NF‐κB p65 and type I interferon in innate immunity to rhinovirus | |
| Tang et al. | Forkhead box protein p1 is a transcriptional repressor of immune signaling in the CNS: implications for transcriptional dysregulation in Huntington disease | |
| Horiuchi et al. | Genome-wide analysis reveals unique regulation of transcription of Th2-specific genes by GATA3 | |
| Coffre et al. | Combinatorial control of Th17 and Th1 cell functions by genetic variations in genes associated with the interleukin‐23 signaling pathway in spondyloarthritis | |
| Lauber et al. | Transcriptome analysis reveals a classical interferon signature induced by IFNλ4 in human primary cells | |
| JP2009000113A (ja) | 細胞移動アッセイ | |
| US11680296B2 (en) | Mycobacterium tuberculosis host-pathogen interaction | |
| Jung et al. | Single-cell genomics for investigating pathogenesis of inflammatory diseases | |
| Hung et al. | Myeloid-derived IL-33 limits the severity of dextran sulfate sodium–induced colitis | |
| WO2020186235A1 (en) | Compositions and methods for modulating cgrp signaling to regulate intestinal innate lymphoid cells | |
| Baltus et al. | CCR5Δ32 (rs333) polymorphism is associated with the susceptibility to systemic lupus erythematosus in female Brazilian patients | |
| Köhler et al. | Non‐canonical STAT3 function reduces REDD1 transcription | |
| JP2005500854A5 (https=) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20210406 |